Previous close | 22.68 |
Open | 22.95 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 1100 |
Day's range | 22.80 - 23.26 |
52-week range | 20.96 - 39.09 |
Volume | |
Avg. volume | 2,191,157 |
Market cap | 5.874B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 6.38 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.12 (5.04%) |
Ex-dividend date | 24 Feb 2023 |
1y target est | N/A |
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Organon (NYSE:OGN), a global women's healthcare company, today announced its formal commitment to FP2030 to help prevent 120 million unintended pregnancies by 2030. Recognizing the urgency of the crisis, Organon is taking action to scale access to contraceptive options for more than 100 million women in low- and middle-income countries (LMICs), in addition to strategic partnerships focused on education, training, advocacy and youth engagement.